16 results about "Cyclohexanecarboxylic acid" patented technology

The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.

The present disclosure relates to a crystalline form of trans-4-[1-(3-Chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and its use as a therapeutic agent to treat inflammatory diseases.

A production method according to one embodiment is a method for producing 4-(aminomethyl)cyclohexane-1-carboxylic acid from 1,4-bis(aminomethyl)cyclohexane using a protein consisting of an amino acid sequence having 60% or more identity to an amino acid sequence shown in any one of SEQ ID NOs. 1 to 4 and 103 to 105 and having transamination activity, and a protein consisting of an amino acid sequence having 50% or more identity to an amino acid sequence shown in any one of SEQ ID NOs. 19 to 22, 35 to 46 and 127 to 139 and having aldehyde dehydrogenase activity.

The application discloses a trienomycin photoaffinity probe, a preparation method and application, and comprises the following steps: taking Trienomycinol as a substrate, carrying out a substitution reaction with an iodine-substituted bisaziridine, then removing propylidene protection to obtain a corresponding photoaffinity negative probe; using Fmoc-D-alanine to selectively esterify a hydroxyl group at position 11 of the negative probe, then removing an Fmoc protection group on nitrogen and carrying out condensation with cyclohexanecarboxylic acid to obtain a corresponding photoaffinity positive probe; trienomycin protein target identification comprises the following steps: (1) enrichment of an intermediate Trienomycinol and synthesis of a trienomycin photoaffinity positive probe; (2) target identification of trienomycin by using the photoaffinity probe and molecular biology research on the target. The separated trienomycin intermediate, the synthesized trienomycin probe derivative and the identified trienomycin protein target have the advantages of high originality and high yield.

The invention discloses a centrifugal filter device for producing alkyl cyclohexyl cyclohexanecarboxylic acid, which comprises an outer sleeve barrel, a variable-frequency transmission component is mounted in the outer sleeve barrel, bent connecting rods are fixedly mounted on two sides of the bottom of the outer sleeve barrel, and a fixing plate is fixedly mounted at one end, far away from the outer sleeve barrel, of each bent connecting rod. A driving assembly is fixedly installed at the bottom of the fixing plate, two connecting columns are fixedly installed at the bottom of the fixing plate, a communicating box is fixedly installed at the bottoms of the two connecting columns, and the bottom of the communicating box communicates with a liquid discharging pipe; through the arrangement of the variable-frequency transmission assembly, the device can continuously change the rotating speed of the throwing and filtering assembly, and the centrifugal force can be dynamically adjusted through continuous speed change, so that substances with different densities and particle sizes are subjected to the action of different centrifugal forces in the centrifugal process. The dynamic centrifugal force adjustment can more thoroughly separate dry and wet components in the materials, and compared with a traditional stable-speed throwing and filtering device, the separation effect is more remarkable.

This invention relates to the field of pharmaceutical synthesis technology, specifically to a method for synthesizing key intermediates of telexamine, aiming to solve the problems of expensive raw materials, high pollution, high safety risks, and unsuitability for industrial production in existing telexamine intermediate synthesis processes. The key intermediates of this invention are 2-(2-thienyl)cyclohexanone and 2-bromo-2-(2-thienyl)cyclohexanone. The synthesis method uses thiophene and cyclohexanecarboxylic acid as starting materials, and obtains 2-(2-thienyl)cyclohexanone through a solvent-free condensation reaction mediated by polyphosphoric acid, followed by bromination with a brominating reagent and purification in an alcohol phase to obtain 2-bromo-2-(2-thienyl)cyclohexanone. This invention uses inexpensive and readily available raw materials, operates under mild conditions, is simple to operate, is environmentally friendly and safe, and achieves a target product yield of up to 73% and an HPLC purity of up to 98.22%, significantly reducing the synthesis cost of telexamine and making it suitable for large-scale industrial production.

The application provides a synthesis method of piperquilon and belongs to the technical field of drug synthesis. The synthesis method uses cheap and easily available glycine and cyclohexyl chloride as starting materials to synthesize cyclohexanecarboxylic acid glycine, and then through a photocatalytic radical deacidification Minisci reaction strategy, the cyclohexanecarboxylic acid glycine is reacted with isoquinoline to efficiently prepare a key intermediate N-(1-isoquinolin-1-ylmethyl)-cyclohexanecarboxamide, and finally piperquilon is synthesized. Compared with the prior art, the synthesis method has the advantages of cheap and easily available raw materials, simple and safe reaction operation, mild reaction conditions, low catalyst dosage (as low as 0.01 mol %) for photo-reaction, simple post-reaction treatment, high yield and the like, and provides a new possible scheme for the industrialized scale preparation of piperquilon.

The present invention relates to a process for the preparation of (1R, 2S, 5R)-1-amino-5-[2-(dihydroxyboryl) ethyl]-2-[(dimethylamino) methyl] cyclohexane-1-carboxylic acid in the form A of crystal. The present invention further relates to methyl (1R, 2R, 4R)-2-acetamido-2-(tert-butylcarbamoyl)-4-(2-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxacyclopentboran-2-yl) ethyl) cyclohexane-1-formate, which is an intermediate in the process.

A production method according to one embodiment of the present invention comprises: using a compound represented by general formula (1) as a substrate compound or an intermediate compound; a method for producing cis-and / or trans-4-(aminomethyl) cyclohexane-1-carboxylic acid in the presence of at least one enzyme selected from the group consisting of a protein having an activity of converting an aldehyde group into a carboxyl group and a protein having an activity of reversibly converting an aldehyde group into an amino group. [In the formula, R1 and R2 are each independently CH2OH, CHO, COOH, or CH2NH2 (however, when one of R1 and R2 is COOH and the other is CH2NH2, and when both R1 and R2 are COOH)]. Specifically, the compound represented by general formula (1) is any one of compounds 1, 2, 3, 4, 5, 6, 7, and 8.

A bicyclic peptide composition and its application are disclosed, relating to the field of peptide technology. The cyclic peptide composition comprises component X and component Y, wherein component X is cyclic tetrapeptide-24-aminocyclohexanecarboxylate, and component Y is selected from one or more of the following cyclic peptides: cyclic hexapeptide-8, cyclic octapeptide-69, Cyclo-(Gly-His-Lys-Lys), Cyclo-(Arg-Arg-Gln-D-Met-Glu-Glu), Cyclo-(Pro-Lys-Glu-Lys), and Cyclo-(Val-Leu-Gln-Trp-Val-Lys). Specifically, the cyclic peptide composition and its use in the preparation of cosmetics are discussed.

To provide a therapeutic or preventive pharmaceutical drug for a disease selected from ocular dryness, vaginal dryness and oral burning syndrome.SOLUTION: According to the present invention, for example, the treatment of above disease is performed using a TRPM8 agonist selected from ethyl 3-(p-methane-3-carboxamide), (-)-isopulegol, (+)-cis and (-)-trans p-methane-3,8-diol, (-)-cubebol, icilin, 5-methyl-4-(1-pyrrolidinyl)-3-[2H]-furanone, 4,5-dimethyl-3-(1-pyrrolidinyl)-2 [5H]-furanone, 4-methyl-3-(1-pyrrolidinyl)-2[5H]-furanone, N-ethyl-p-methane-3-carboxamide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid (2-hydroxy-1,1-dimethyl-ethyl acid)-amide, 2-isopropyl-5-methyl-cyclohexane carboxylic acid (4-methoxyphenyl) amide, etc.SELECTED DRAWING: None

The application discloses a kind of wide band gap perovskite solar cell based on bottom interface modification and preparation method thereof, its device structure sequentially includes conductive substrate, hole transport layer, interface modification layer, perovskite functional layer, electron transport layer and metal electrode layer from bottom to top, wherein the interface modification layer contains trans-4-guanidyl cyclohexane carboxylic acid (t-GCHA) and its derivative additive.The wide band gap perovskite solar cell containing trans-4-guanidyl cyclohexane carboxylic acid and its derivative interface modification is obtained by spin-coating solution containing such additive on the hole transport layer to form interface modification layer, using the bifunctional group characteristics of guanidyl and carboxyl in molecule, the effective passivation to buried bottom interface defect and the optimization of energy level arrangement are realized, the film forming quality of perovskite film is improved, so that perovskite solar cell with excellent photoelectric performance is further prepared.The preparation process of the application is simple, low in cost, and helps the commercialization of perovskite solar cell.

The present disclosure relates to crystalline forms of trans-4-[1-(3-chloro-phenyl)-7-methoxy-2,4-dioxo-3,4-dihydro-2H-pyrimido[5,4-c]quinolin-3-yl]-cyclohexanecarboxylic acid hydrochloride, methods of preparation, and their use as therapeutic agents for the treatment of inflammatory diseases.

Disclosed are a bicyclic peptide composition and application thereof in skin care, and relate to the technical field of polypeptides, the composition comprising s-mu-conotoxin CnIIIC and a cyclic tetrapeptide-24 aminocyclohexane formate ester.The composition can be used for oil control, acne removal, repair, tightening, wrinkle reduction or anti-aging.

The invention discloses a method for degrading naphthenic acid by electrocatalytic anaerobic microorganisms, and belongs to the field of wastewater treatment. Comprising the following steps: (1) carrying out a domestication enrichment experiment by using anaerobic granular sludge to obtain domesticated sludge; (2) the domesticated sludge is mainly characterized in that a key core flora is obtained, and the key core flora comprises the door of Halobacteria, the door of Chloroflexota and the door of Bacteroidota, and the door of Chloroflexota, the door of Bacteroidota, the door of Chloroflexota, the door of Bacteroidota, the door of Chloroflexota and the door of Bacteroidota; and (3) in a bioelectrochemical system, carrying out naphthenic acid degradation on the domesticated sludge under a 1-3V power-up condition, taking 80-200mg / L of cyclohexanecarboxylic acid as a unique carbon source, adopting a mesh electrode plate comprising Ta2O5, IrO2 and Ti as an anode, and adopting a stainless steel mesh electrode plate as a cathode. The method provided by the invention can achieve the effects of efficiently removing naphthenic acid and quickly optimizing the composition of the microbial community.